2023–2033 Forecast: Human Coagulation Factor VII Market to Triple in Size as Demand and Innovation Accelerate | Predicts $6.5B Value
Human coagulation factor VII (FVII) is a vitamin K-dependent serine protease synthesized in the liver, circulating in plasma primarily as an inactive zymogen. It helps to stop bleeding when blood vessels are damaged. FVII deficiency can lead to bleeding disorders.
Allied Market Research released a report on the human coagulation factor VII industry, which provid... more2023–2033 Forecast: Human Coagulation Factor VII Market to Triple in Size as Demand and Innovation Accelerate | Predicts $6.5B Value
Human coagulation factor VII (FVII) is a vitamin K-dependent serine protease synthesized in the liver, circulating in plasma primarily as an inactive zymogen. It helps to stop bleeding when blood vessels are damaged. FVII deficiency can lead to bleeding disorders.
Allied Market Research released a report on the human coagulation factor VII industry, which provides industry dynamics, including growth drivers, opportunities, and challenges. This report further offers regional analysis and a competitive landscape of the domain. The sector accounted for $2.6 billion in 2023 and is anticipated to reach $6.5 billion by 2033, growing at a CAGR of 9.4% during the forecast period.
👉 Download Free PDF (Only For Today) ✔
https://www.alliedmarketresearch.com/request-sample/A324440
The report offers a thorough analysis of the human coagulation factor VII market with detailed study of various aspects of the market such as market dynamics, vital segments, major countries, key players, and competitive landscape. It provides a clear picture of the current market situation, and the future trends of the human coagulation factor VII market based on the impact of various market dynamics and vital forces influencing the market. The drivers and opportunities contributing to market growth are acknowledged in the market dynamics.
Advancements in recombinant DNA and biotechnological manufacturing lead to production of high-purity recombinant FVIIa. This reduces reliance on plasma-derived products and lowers the risks of viral or prion transmission. Rise in awareness about improvement of diagnostics and early identification of bleeding disorders also fosters market growth. There is a rise in usage of FVIIa in non-congenital bleeding settings, which include surgical, trauma, and emergency medicine contexts. This increases the demand for human coagulation factor VII across the healthcare sector. However, the high cost of therapy limits the growth of the market. In addition, FVII deficiency is rare, which leads to small market size, which, in turn, reduces the revenue potential. Thus, this factor restrains the growth of the human coagulation factor VII industry landscape. Nevertheless, emerging economies lead to improvements in infrastructure and increase awareness of bleeding disorders. This is projected to foster the growth of the human coagulation factor VII market in the upcoming years.
Important questions
What are the key factors driving the growth of this industry?
Which companies are the leading players in the domain?
Which application leads the human coagulation factor VII market?
What are the factors that restrain the growth of the sector?
What is the dominating segment based on the end user?
Regional Insights
North America and Europe boast a well-developed healthcare system along with strong reimbursement frameworks. These factors boost the growth of the human coagulation factor VII market in North America and Europe. Emerging economies, LAMEA and Asia-Pacific, exhibit rapid growth potential owing to increase in healthcare infrastructure investments, rise in awareness about bleeding disorders, and expansion of diagnostics.
List of Key Players
Key players studied in the human coagulation factor VII market include
Baxter International Inc.
CSL Behring
Novo Nordisk
Grifols USA LLC
Pfizer Inc.
Bayer AG
ProSpec
Octapharma AG
Sanofi
Tany Technogene Ltd.
These players have adopted various strategies to sustain their foothold in the competitive market. Some of these strategies include product launch, agreement, collaboration, and others.
Conclusion
The report offers Porter's Five Forces analysis to present an overview of the market structure to its stakeholders. It also studies various aspects of the sector. These include competitive rivalry, threat of new entrants, and bargaining power of suppliers and buyers and provides necessary information to the investors, stakeholders, and new market entrants seeking a thorough understanding of the global human coagulation factor VII market landscape.
Contact Us:
United States
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int’l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
help@alliedmarketresearch.com
